Oncological and functional outcome of robotic‐assisted radical cystectomy with total intracorporeal stentless J‐pouch neobladder reconstruction

Background Robotic‐assisted radical cystectomy (RARC) with neobladder reconstruction has gained popularity in recent years. Methods We conducted a retrospective study of 17 consecutive patients who underwent RARC with totally intracorporeal J‐pouch neobladder reconstruction without ureteral stent by a single experienced surgeon to evaluate perioperative, oncological and functional outcomes. Results The median follow‐up duration was 32.8 months (range: 17.4–59.0 months), and the 2‐year disease‐free survival rate was 88.2%. Five out of 12 patients were totally continent, and none required more than one pad per day. The overall complication rate was 41.2%, and hydronephrosis was the most common adverse event. The renal function remained stable, and no long‐term renal function impairment was detected. Conclusion Our study suggests that RARC with totally intracorporeal J‐pouch neobladder reconstruction without ureteral stent is a safe and feasible option for the treatment of muscle‐invasive bladder cancer, with good oncological and functional outcomes.